Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Kiniksa management to meet virtually with Wedbush » 04:55
09/21/21
09/21
04:55
09/21/21
04:55
KNSA

Kiniksa

$11.80 /

-0.4 (-3.28%)

Virtual Meetings to be…

Virtual Meetings to be held on September 20-21 hosted by Wedbush.

ShowHide Related Items >><<
KNSA Kiniksa
$11.80 /

-0.4 (-3.28%)

KNSA Kiniksa
$11.80 /

-0.4 (-3.28%)

08/04/21 Wedbush
Kiniksa price target lowered to $24 from $32 at Wedbush
03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$11.80 /

-0.4 (-3.28%)

Conference/Events
Kiniksa management to meet virtually with Wedbush » 04:55
09/20/21
09/20
04:55
09/20/21
04:55
KNSA

Kiniksa

$12.20 /

+0.27 (+2.26%)

Virtual Meetings to be…

Virtual Meetings to be held on September 20-21 hosted by Wedbush.

ShowHide Related Items >><<
KNSA Kiniksa
$12.20 /

+0.27 (+2.26%)

KNSA Kiniksa
$12.20 /

+0.27 (+2.26%)

08/04/21 Wedbush
Kiniksa price target lowered to $24 from $32 at Wedbush
03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$12.20 /

+0.27 (+2.26%)

Over a month ago
Conference/Events
Kiniksa management to meet virtually with Wedbush » 10:21
09/14/21
09/14
10:21
09/14/21
10:21
KNSA

Kiniksa

$12.34 /

+0.01 (+0.08%)

Virtual Meetings to be…

Virtual Meetings to be held on September 20-21 hosted by Wedbush.

ShowHide Related Items >><<
KNSA Kiniksa
$12.34 /

+0.01 (+0.08%)

KNSA Kiniksa
$12.34 /

+0.01 (+0.08%)

08/04/21 Wedbush
Kiniksa price target lowered to $24 from $32 at Wedbush
03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$12.34 /

+0.01 (+0.08%)

Hot Stocks
Kiniksa announces launch of ARCALYST named patient program » 08:31
08/16/21
08/16
08:31
08/16/21
08:31
KNSA

Kiniksa

$12.24 /

-0.19 (-1.53%)

Kiniksa Pharmaceuticals…

Kiniksa Pharmaceuticals announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling. The Named Patient Program for ARCALYST was launched in partnership with the specialist services company, WEP Clinical. The program is designed to ensure that physicians outside the U.S. can request ARCALYST on behalf of individual patients who have recurrent pericarditis, cryopyrin-associated periodic syndromes, or deficiency of IL-1 receptor antagonist but reside in countries where ARCALYST is not currently commercially available.

ShowHide Related Items >><<
KNSA Kiniksa
$12.24 /

-0.19 (-1.53%)

KNSA Kiniksa
$12.24 /

-0.19 (-1.53%)

08/04/21 Wedbush
Kiniksa price target lowered to $24 from $32 at Wedbush
03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$12.24 /

-0.19 (-1.53%)

KNSA Kiniksa
$12.24 /

-0.19 (-1.53%)

Recommendations
Kiniksa price target lowered to $24 from $32 at Wedbush » 07:27
08/04/21
08/04
07:27
08/04/21
07:27
KNSA

Kiniksa

$13.77 /

-2.47 (-15.21%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on Kiniksa to $24 from $32 and keeps an Outperform rating on the shares after the company reported Q2 earnings and updated its pipeline activity. The analyst's target change is a result of extending the anticipated launch of vixarelimab out two years and reducing the time to peak penetration of ARCALYST from 120 months to 66 months.

ShowHide Related Items >><<
KNSA Kiniksa
$13.77 /

-2.47 (-15.21%)

KNSA Kiniksa
$13.77 /

-2.47 (-15.21%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$13.77 /

-2.47 (-15.21%)

KNSA Kiniksa
$13.77 /

-2.47 (-15.21%)

Hot Stocks
Kiniksa expects cash to fund operating plan into 2023 » 08:07
08/03/21
08/03
08:07
08/03/21
08:07
KNSA

Kiniksa

$16.21 /

+0.84 (+5.47%)

Kiniksa expects that its…

Kiniksa expects that its cash, cash equivalents and short-term investments will fund its current operating plan into 2023.

ShowHide Related Items >><<
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

Hot Stocks
Kiniksa sees Q3 ARCALYST net revenue $9M-$10M.  08:07
08/03/21
08/03
08:07
08/03/21
08:07
KNSA

Kiniksa

$16.21 /

+0.84 (+5.47%)

 
ShowHide Related Items >><<
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

Earnings
Kiniksa reports Q2 EPS (61c), consensus (79c) » 08:06
08/03/21
08/03
08:06
08/03/21
08:06
KNSA

Kiniksa

$16.21 /

+0.84 (+5.47%)

Reports Q2 revenue $7.7M,…

Reports Q2 revenue $7.7M, consensus $3.97M. "Our commercial team is doing a superb job with the launch of ARCALYST in recurrent pericarditis," said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. "Feedback received from physicians and patients highlights the transformational potential of ARCALYST for patients suffering from recurrent pericarditis. We have seen strong uptake and look forward to using this momentum to accelerate broader adoption across this underserved population."

ShowHide Related Items >><<
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

KNSA Kiniksa
$16.21 /

+0.84 (+5.47%)

Over a quarter ago
Hot Stocks
Magenta Therapeutics appoints Thomas Beetham as chief legal officer » 08:12
06/14/21
06/14
08:12
06/14/21
08:12
MGTA

Magenta Therapeutics

$11.57 /

-0.15 (-1.28%)

, KNSA

Kiniksa

$14.85 /

+0.02 (+0.13%)

Magenta Therapeutics…

Magenta Therapeutics (MGTA) announced the appointment of Thomas Beetham as chief legal officer. As chief legal officer, Beetham will serve as a member of the company's executive team and will be responsible for leading all aspect of Magenta's legal and compliance operations. Beetham comes to Magenta with more than 20 years of experience in legal, business development, operations and strategy across the biotechnology and pharmaceutical industries. He joins Magenta most recently from Kiniksa (KNSA), where he served as chief legal officer and executive VP where he oversaw all company legal matters, including transactions, financings, corporate and securities, public company reporting, tax, international, real estate, human resources and more.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

KNSA Kiniksa
$14.85 /

+0.02 (+0.13%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
KNSA Kiniksa
$14.85 /

+0.02 (+0.13%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
07/17/20 JPMorgan
Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

KNSA Kiniksa
$14.85 /

+0.02 (+0.13%)

  • 22
    Jul
  • 25
    Jun
KNSA Kiniksa
$14.85 /

+0.02 (+0.13%)

Hot Stocks
Kiniksa announces U.S. patent for treatment of recurrent pericarditis » 16:09
06/08/21
06/08
16:09
06/08/21
16:09
KNSA

Kiniksa

$14.24 /

+0.49 (+3.56%)

Kiniksa Pharmaceuticals…

Kiniksa Pharmaceuticals announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST in the treatment of recurrent pericarditis. The patent issued as U.S. Patent No. 11,026,997 and will expire on March 11, 2039. Kiniksa has exclusive rights to this patent under the ARCALYST License Agreement. "We believe this patent continues to strengthen our proprietary position on the FDA-approved use of ARCALYST in recurrent pericarditis and provides protection that extends approximately 11 years beyond orphan drug exclusivity and into 2039," said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. "We continue to execute on our commercial strategy and look forward to providing our first full quarter ARCALYST sales in our second quarter earnings report."

ShowHide Related Items >><<
KNSA Kiniksa
$14.24 /

+0.49 (+3.56%)

KNSA Kiniksa
$14.24 /

+0.49 (+3.56%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
07/17/20 JPMorgan
Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
KNSA Kiniksa
$14.24 /

+0.49 (+3.56%)

  • 22
    Jul
KNSA Kiniksa
$14.24 /

+0.49 (+3.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.